Virtually Attend the 2020 SITC Cancer Immunotherapy Winter School
SITC is pleased to host its third annual Cancer Immunotherapy Winter School, a comprehensive cancer immunotherapy education program, which will be held virtually on Feb. 22–24, 2021. Taught by leading experts in the field, this program provides a deep understanding of the core principles of tumor immunology and cancer immunotherapy as well as developing areas in the field including biomarker technology, validation and clinical integration; clinical trial design, data analysis and considerations for combination therapies.
Winter School Organizers:
- Christian Capitini, MD – University of Wisconsin-Madison
- Leisha A. Emens, MD, PhD – UPMC Hillman Cancer Center
- Daniel Powell, PhD – University of Pennsylvania
The Cancer Immunotherapy Winter School program is tailored to early-to-mid career scientists and clinicians in the field of cancer immunotherapy working in academic, clinical, industry and government settings as well as those new to the field. The curriculum covers the fundamentals of cancer immunotherapy and features separate tracks, including clinical and research, allowing participants to tailor their experience by selecting the educational path most relevant to their learning goals.
Click here to view registration rates for this program and then register now to confirm your attendance.
Explore the SITC Clinical Practice Guidelines
SITC Cancer Immunotherapy Guidelines are a collection of clinical practice guidelines (CPGs) developed by multi-disciplinary panels of leading experts help healthcare providers determine when and how to best use immunotherapy to treat their patients. The evidence- and expert consensus-based recommendations within the CPGs are developed using the Institute of Medicine's 2011 "Standards for Developing Trustworthy Clinical Practice Guidelines" as a model to ensure a fair, transparent and balanced process. Offering practical guidance on topics including biomarkers, treatment selection, response monitoring, toxicity management and quality of life, the SITC CPGs are vital resource for the oncology community.
Published in the Journal for ImmunoTherapy of Cancer (JITC), the society’s open access, peer-reviewed online journal, the guidelines are freely available to the community. Additionally, SITC hosts free, live webinars for each guideline as an added opportunity for practitioners to deepen their learning on immunotherapy. This past year, reflecting the recent advancements in immunotherapy for blood cancers, SITC published two standalone guidelines on hematologic malignancies, specifically, multiple myeloma and acute leukemia, and guideline on lymphoma has been accepted for publication in JITC. Also publishing soon is a CPG specifically devoted to toxicity management for immune effector cell therapies.
As immunotherapy increasingly becomes the standard of care and moves into earlier lines of treatment for a variety of tumor types, several additional CPGs are currently in development, representing both updates to previously published guidelines as well as covering new disease settings.
Published SITC Guidelines:
SITC Guidelines in Development: